Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of enGene Holdings Inc. from 31 Oct 2022 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
enGene Holdings Inc. annual and quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Oct 2022 to 31 Oct 2025.
  • enGene Holdings Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Jan 2025 was $110,658,000, a 2783% decline year-over-year.
  • enGene Holdings Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2025 was $122,852,000, a 234% decline from 2024.
  • enGene Holdings Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $91,483,000, a 50% increase from 2023.
  • enGene Holdings Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $61,087,000, a 549% increase from 2022.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)

enGene Holdings Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $122,852,000 -$214,335,000 -234% 01 Nov 2024 31 Oct 2025 10-K 22 Dec 2025 2025 FY
2024 $91,483,000 +$30,396,000 +50% 01 Nov 2023 31 Oct 2024 10-K 22 Dec 2025 2025 FY
2023 $61,087,000 +$51,670,000 +549% 01 Nov 2022 31 Oct 2023 10-K 19 Dec 2024 2024 FY
2022 $9,417,000 01 Nov 2021 31 Oct 2022 10-K 29 Jan 2024 2023 FY

enGene Holdings Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $110,658,000 -$114,783,000 -2783% 01 Nov 2024 31 Jan 2025 10-Q 10 Mar 2025 2025 Q1
Q4 2023 $4,125,000 +$10,370,000 01 Nov 2023 31 Jan 2024 10-Q 10 Mar 2025 2025 Q1
Q4 2022 $6,245,000 01 Nov 2022 31 Jan 2023 10-Q 11 Mar 2024 2024 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.